Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer

NCT04115306 is registered in ClinicalTrials.gov with Phoenix Molecular Designs as lead sponsor.

NCT NCT04115306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer
Lead sponsor
Phoenix Molecular Designs
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 14, 2019
Completion date
December 31, 2026
Enrollment
61 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer